Litfulo access guide: country options for cross-border named-patient access

Editorial and clinical review: Reserve Meds clinical and regulatory team. Last reviewed 2026-06-04.

About Litfulo

Litfulo (ritlecitinib) is a Janus kinase 3 and TEC kinase family (JAK3 / TEC) inhibitor approved by the US Food and Drug Administration for severe alopecia areata in adults and adolescents 12 years and older. The current FDA label is available at accessdata.fda.gov. Litfulo is marketed by Pfizer. Reserve Meds coordinates US-sourced cross-border access to Litfulo under the named-patient and personal-import framework that governs reference-authority-approved medicines in the patient jurisdiction, with chain-of-custody documentation under the US Drug Supply Chain Security Act (DSCSA). The country-specific access guides listed below set out the regulatory pathway, the tertiary referral context, the documentation bundle the treating physician of record submits to the regulator, and the indicative drug-only cash-pay band for Litfulo in each jurisdiction Reserve Meds has authored.

Litfulo country-specific access guides

Reserve Meds has published 4 country-specific access guides for Litfulo. Each guide covers the regulatory pathway, the tertiary referral context, the documentation package, the indicative drug-only band, and the operational sequence Reserve Meds coordinates for that jurisdiction.

Other countries not yet authored

Reserve Meds has authored country-specific access guides for Litfulo in the 4 jurisdictions listed above. If your case sits in a country that is not yet on this list, that does not mean a pathway is unavailable. It means we have not yet published the country-specific guide for Litfulo. The Reserve Meds case team will scope your case under the same named-patient or personal-import framework that governs the published guides.

Request a Litfulo access scope for your country

Related Reserve Meds resources

• Access pathways index (named-patient, personal-import, hospital-exemption, and equivalent frameworks by country)
• Conditions index (the indication families Reserve Meds coordinates around)
• Drug catalog (all FDA-labeled medicines in the Reserve Meds coordination scope)
• All country-specific access guides
• How Reserve Meds coordinates a cross-border case
• Trust, compliance, and editorial review

---

Composite case examples; no individual patient is depicted. This content is for general information and does not constitute medical advice. Reserve Meds is a US-based concierge coordinator; we are not the prescriber and not the dispensing pharmacy. Clinical decisions remain with your treating physician.

Editorial review: Reserve Meds clinical and regulatory team. Last reviewed 2026-06-04.